Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2026), Lancet Infect Dis, 26, 34 - 45
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2025), Lancet Infect Dis, 25, 1000 - 1010
High-Dose vs. Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial
Skaarup KG. et al, (2025), Circulation: Heart Failure
Risk of Myocarditis or Pericarditis with High-Dose versus Standard-Dose Influenza Vaccine: A Prespecified Analysis of the Randomized DANFLU-2 Trial
LANDRAY M. et al, (2025), JAMA Network Open
Recommended methodologies for clinical investigations of high-risk medical devices – Conclusions from the European Union CORE–MD Project
LANDRAY M. et al, (2025), The Lancet Regional Health. Europe
High-dose versus standard-dose inactivated influenza vaccine and cardiovascular risk: the DANFLU-2 trial
LANDRAY M. et al, (2025), European Heart Journal
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Zhou J. et al, (2025), EClinicalMedicine, 85
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2025), Nephrol Dial Transplant, 40, 1175 - 1186
Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression.
Greene T. et al, (2025), Clin J Am Soc Nephrol, 20, 632 - 641
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Correction: Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience.
Buccheri S. et al, (2025), Trials, 26
Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience.
Buccheri S. et al, (2025), Trials, 26
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Judge P. et al, (2024), Nephrology Dialysis Transplantation
Accelerating Evidence Generation: Addressing Critical Challenges and Charting a Path Forward
LANDRAY M., (2024), Journal of Clinical and Translational Science
Overcoming the barriers to better evidence generation from clinical trials
LANDRAY M., (2024), Trials